Invicta Diagnostic Reports Strong FY26 Performance: Total Income Reaches ₹ 33.04 Cr

Invicta Diagnostic Reports Strong FY26 Performance: Total Income Reaches ₹ 33.04 Cr​

Invicta Diagnostic Limited, a key player in Maharashtra's diagnostic service sector, has reported its Audited Financial Results for the second half (H2) and full fiscal year (FY) 2026. The company announced strong financial results, highlighting a significant increase in total income and maintaining robust EBITDA margins.

According to the reported financials, the company achieved a total income of ₹ 33.04 Cr for the full financial year 2026. During the second half of FY26, the total income stood at ₹ 15.96 Cr.

Financial Results Overview​

The company's financial performance showed improvement year-over-year, particularly in overall profitability metrics.


The company noted that during FY26, it invested in its long-term growth strategy and network expansion, which resulted in a cash outflow of ₹ 12.96 Cr towards the purchase of fixed assets. The depreciation expense also rose to ₹ 3.25 Cr in FY26, an increase from ₹ 2.49 Cr in FY25, primarily due to a higher asset base. Invicta Diagnostic stated that as new centers mature and scale up operations, the company anticipates improved operating leverage and stronger revenue contribution in the coming periods.

Key Operational Milestones​

Invicta Diagnostic has expanded its footprint across Maharashtra through several strategic initiatives:

• Strategic Entry into Pune: The company entered the Pune market via a strategic joint venture (JV) with four prominent radiologists. Invicta holds a 52% stake, ensuring management control and operational oversight. The group is currently evaluating opportunities to establish additional diagnostic centers in Pune over the next one to two years. The first center is located at Market Yard, Pune.
• Dadar Centre Commences Operations: Commercial operations began at the Dadar Centre on January 30, 2026. This advanced facility is strategically located near Tata Memorial Hospital in a high-demand oncology diagnostics cluster. The center offers PET-CT, CT scan, Sonography, Pathology, and X-Ray services and was established with an investment of approximately ₹ 5.50 Cr.
• Entry into Nashik: Invicta successfully completed the first phase of its strategic acquisition into the Nashik healthcare market by securing a 51% controlling stake in Vinchurkar Diagnostics Private Limited on May 8, 2026. The company received approval to acquire up to 95% stake in Vinchurkar Diagnostics Private Limited, with the total consideration for the phased acquisition set at ₹ 7.60 Cr.

Management Commentary​

Sanket Vinod Jain, Chairman and Non-Executive Director of Invicta Diagnostic Limited, commented on the performance, stating that FY26 was a landmark year for the company.

"During FY26, we reported a Total Income of ₹ 33.04 Cr and maintained EBITDA margins in excess of 30%, reflecting strong operating efficiency and disciplined execution," said Mr. Jain.

He added that the strategic movements, including the Pune entry, the launch of the advanced Dadar Centre near Tata Memorial Hospital, and the acquisition in Nashik, are set to strengthen the platform for long-term growth across Maharashtra. Invicta remains focused on expanding its diagnostics network and driving sustainable growth in FY27.

INVICTA Stock Price Movement​

Invicta Diagnostic Limited shares today slipped by 5.00% to settle at ₹80.80. The stock saw a total traded volume of 1,600 shares, reflecting selling pressure during post-market trading.